Kite Pharma Inc. (KITE) 57.56 $KITE
Juno Therapeutics Gets Lift From Cancer Test Results
at Investor's Business Daily - Tue Apr 21, 1:57PM CDT
Juno Therapeutics' (JUNO) stock rebounded Tuesday as the company reported "highly encouraging" results from a clinical trial on pediatric patients with leukemia, after shares fell sharply Monday. Juno is developing cellular immunotherapies to treat...
BLCM: 28.55 (+2.59), KITE: 57.56 (-1.43), JUNO: 55.72 (-0.68), NVS: 103.45 (-0.62)
Kite Pharma Commends Honors Conferred to Drs. Owen Witte and Steven A. Rosenberg at the 2015 American Association for Cancer Research (AACR) Annual Meeting
GlobeNewswire - Tue Apr 21, 12:30PM CDT
Kite Pharma, Inc. (Kite) (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT(TM)) products for the treatment of cancer, today announced that Owen Witte, M.D., director of the Eli & Edythe Broad Center of Regenerative Medicine & Stem Cell Research at UCLA, is being honored at this year's AACR conference as he receives the prestigious G.H.A. Clowes Memorial Award. In addition, Steven A. Rosenberg, M.D., Ph.D., Chief of Surgery at the National Cancer Institute (NCI), has been inducted into the 2015 Class of Fellows of the AACR Academy. Dr. Witte is a scientific founder of Kite Pharma, serving on Kite's Scientific Advisory Board, and Dr. Rosenberg is a special advisor to Kite.
KITE: 57.56 (-1.43)
Earnings Insights - Kite Pharma
PR Newswire - Tue Apr 21, 8:30AM CDT
Editor Note: For more information about this release, please scroll to bottom.
KITE: 57.56 (-1.43), AMGN: 169.10 (+0.64)
Why Shares of Juno Therapeutics Inc. and Kite Pharma Inc. Crashed Today
Alex Planes, The Motley Fool - Motley Fool - Mon Apr 20, 5:59PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of biotech upstarts Juno Therapeutics and ...
ZIOP: 10.88 (+0.03), KITE: 57.56 (-1.43), JUNO: 55.72 (-0.68), NVS: 103.45 (-0.62)
AACR - Solid Tumour CAR-T Foray Lives Up To Its Low-Key Billing
EP Vantage - at Seeking Alpha - Mon Apr 20, 3:58PM CDT
For some time now solid tumours has been seen as the next big battleground for CAR-T therapy, but based on the underwhelming early data released yesterday at the AACR meeting the best that can be said is that the jury is still out. A very early...
KITE: 57.56 (-1.43), MRK: 57.69 (+0.03), JUNO: 55.72 (-0.68), NVS: 103.45 (-0.62)
Juno, Kite CAR-T Stocks Fall on Disappointing Solid Tumor Data
at The Street - Mon Apr 20, 9:22AM CDT
Shares of Juno Therapeutics and Kite Pharma are weak Monday following a lackluster showing for so-called CAR-T cellular therapies in solid tumors at a closely watched cancer conference this weekend.
ZIOP: 10.88 (+0.03), BLCM: 28.55 (+2.59), KITE: 57.56 (-1.43), JUNO: 55.72 (-0.68)
NeoStem Announces Expanded Cell Therapy Manufacturing Relationship With Kite Pharma
GlobeNewswire - Mon Apr 20, 6:30AM CDT
NeoStem, Inc. (Nasdaq:NBS), a biopharmaceutical company developing novel cell-based individualized medicine therapies, announced today the expansion of manufacturing services under an existing Services Agreement between its wholly-owned subsidiary, PCT, and Kite Pharma, Inc. (Nasdaq:KITE) (Kite), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT(TM)) products for the treatment of cancer.
KITE: 57.56 (-1.43), NBS: 2.88 (+0.06)
Immune Cell Cancer Immunotherapy Passes First Safety Test in Solid Tumors
at The Street - Sun Apr 19, 11:45AM CDT
The positive phase I safety study was conducted using a CAR-T therapy from Novartis and the University of Pennsylvania.
KITE: 57.56 (-1.43), JUNO: 55.72 (-0.68), NVS: 103.45 (-0.62)
The Top 5 Best IPO Performers in the Last Year
at The Street - Thu Apr 16, 2:56PM CDT
These are the top five best IPO performers in the last 12 months.
RDUS: 41.90 (-0.48), KITE: 57.56 (-1.43), CYBR: 65.53 (-0.84), ONCE: 64.79 (-0.25), ATRA: 63.79 (+7.64)
Etsy, Virtu Price High As IPOs Finally Wake Up
at Investor's Business Daily - Wed Apr 15, 6:45PM CDT
The 2015 IPO market is finally starting to pick up the pace after a relatively sleepy start. Etsy (ETSY), an e-commerce site for handmade goods and vintage items, was one of three notable initial public offerings that priced high in their expected...
XBIT: 27.55 (+0.18), VIRT: 21.81 (-0.54), ADRO: 38.17 (-0.50), KITE: 57.56 (-1.43), PRTY: 20.65 (-0.22), CDTX: 14.94 (-0.11), JUNO: 55.72 (-0.68), ETSY: 25.12 (-0.63)
Critical Alerts For GW Pharmaceuticals, Avon Products, 58.com, Box and Kite Pharma Released By InvestorsObserver
PR Newswire - Wed Apr 15, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for GWPH, AVP, WUBA, BOX and KITE.
WUBA: 75.56 (+3.20), AVP: 8.81 (-0.07), BOX: 18.29 (+0.37), KITE: 57.56 (-1.43), GWPH: 113.04 (-0.05)
Why Kite Pharma (KITE) Could Shock the Market Soon - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Apr 15, 8:00AM CDT
Kite Pharma has seen a small negative price movement but large positive earnings estimate revisions make it an unappreciated stock that might have potential for gains
KITE: 57.56 (-1.43)
Celldex Therapeutics Pushes Forward With Varlilumab And Further Proves Its Worth
Investing Healthcare - at Seeking Alpha - Tue Apr 14, 10:05AM CDT
KITE: 57.56 (-1.43), CLDX: 28.95 (+1.08), BMY: 66.60 (-0.21), ONTY: 1.80 (+0.03)
Heat Biologics Is An Opportunity Among Soaring Immunotherapy Biotech Valuations
Sharon di Stefano - Seeking Alpha - Tue Apr 14, 8:20AM CDT
Vaccination, in medical terminology, is injection of a disease-causing microorganism that stimulates the immune system to fight against infection, using the body's own defense mechanisms. Vaccination has all but wiped out polio, tetanus, chicken pox...
HTBX: 7.71 (-0.64), BLCM: 28.55 (+2.59), KITE: 57.56 (-1.43), PFE: 34.93 (+0.04), MRK: 57.69 (+0.03), CLLS: 31.30 (-0.91), SPPI: 5.98 (+0.04), JUNO: 55.72 (-0.68), BMY: 66.60 (-0.21)
Amgen Upgraded to Strong Buy, Perfect for Your Portfolio - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 13, 2:27PM CDT
On Apr 11, Zacks Investment Research upgraded Amgen Inc. (AMGN) to a Zacks Rank #1 (Strong Buy); is it in your portfolio?
CYTK: 7.29 (-0.09), CBM: 42.07 (-0.65), KITE: 57.56 (-1.43), AMGN: 169.10 (+0.64)
Immunotherapy: Unleashing The Immune System To Decimate Cancer
ARK Investment Management - at Seeking Alpha - Sat Apr 11, 2:51AM CDT
By James Bannon, Analyst: Genomics For more than a century, surgery and poison have been the antidotes to cancer. When tumors are discovered, doctors decide whether or not to remove them surgically. With or without surgery, doctors typically...
KITE: 57.56 (-1.43), MRK: 57.69 (+0.03), AMGN: 169.10 (+0.64), JUNO: 55.72 (-0.68), BMY: 66.60 (-0.21), NVS: 103.45 (-0.62)
Kite Pharma to Present at the 2015 Jefferies Immuno-Oncology Summit in Boston
GlobeNewswire - Fri Apr 10, 7:00AM CDT
Kite Pharma, Inc., (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT(TM)) products for the treatment of cancer, today announced that Arie Belldegrun, M.D., FACS, Chairman, President and Chief Executive Officer, will present a company overview at the 2015 Jefferies Immuno-Oncology Summit in Boston. The presentation will take place on Wednesday, April 15, 2015, at 8:10 a.m. EDT.
KITE: 57.56 (-1.43)
Why Investors Shouldn't Worry About Explosive New Drug Pricing: Maxim's Jason Kolbert
Life Sciences Report - Seeking Alpha - Thu Apr 09, 4:59PM CDT
It's the daring Phase 2-stage molecules of today that will bring patients a generation of biotech drugs that could cure certain deadly diseases tomorrow. The candidates that succeed will also energize the portfolios of investors who have exercised...
PSTI: 2.80 (-0.03), NBS: 2.88 (+0.06), OSIR: 16.35 (-0.10), BCLI: 4.29 (-0.09), MDVN: 128.88 (+0.29), INO: 10.39 (-0.09), CYTX: 0.96 (-0.09), STEM: 0.82 (-0.06), JUNO: 55.72 (-0.68), ATHX: 1.34 (+0.01), CUR: 1.96 (-0.04), BLUE: 136.49 (+1.22), VRTX: 132.85 (+0.65), AMGN: 169.10 (+0.64), KERX: 11.52 (-0.15), OMER: 24.41 (-0.15), KITE: 57.56 (-1.43), GILD: 104.18 (-1.02), MRK: 57.69 (+0.03), TEVA: 63.01 (-1.15)
Another IPO Filed In Hot Cancer Immunotherapy Field
at Investor's Business Daily - Tue Apr 07, 12:55PM CDT
Adaptimmune Therapeutics has filed for an initial public offering, adding another company to one of the hottest sectors in the biotech field. U.K.-based Adaptimmune Therapeutics plans to raise up to $150 million and list on the Nasdaq under the...
BLUE: 136.49 (+1.22), BLCM: 28.55 (+2.59), KITE: 57.56 (-1.43), AMGN: 169.10 (+0.64), JUNO: 55.72 (-0.68)
Kite Pharma Announces Publication in Science of Cancer Immunotherapy Articles Authored by Lead Collaborators at the National Cancer Institute and the Netherlands Cancer Institute
GlobeNewswire - Mon Apr 06, 7:00AM CDT
Kite Pharma, Inc. (Kite) (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT(TM)) products for the treatment of cancer, today announced articles being published in the current issue of Science, one article by the Company's Cooperative Research and Development Agreement (CRADA) collaborators at the National Cancer Institute (NCI) and the second article by the Netherlands Cancer Institute (NKI). The first article, "Adoptive Cell Transfer as personalized immunotherapy for human cancer," was authored by Steven A. Rosenberg, M.D., Ph.D., Chief of Surgery at the NCI, and his colleague Nicholas P. Restifo, M.D., Senior Investigator at NCI's Surgery Branch. The second article, "Neoantigens in cancer immunotherapy," was written by Professor Dr. Ton N. M. Schumacher, Ph.D., Deputy Director of NKI, and Robert D. Schreiber, Ph.D., Director, Center for Human Immunology and Immunotherapy Programs, at Washington University School of Medicine. Professor Schumacher also serves as Chief Scientific Officer of Kite Pharma EU.
KITE: 57.56 (-1.43)
Juno Therapeutics Gets Lift From Cancer Test Results
at Investor's Business Daily - Tue Apr 21, 1:57PM CDT
Juno Therapeutics' (JUNO) stock rebounded Tuesday as the company reported "highly encouraging" results from a clinical trial on pediatric patients with leukemia, after shares fell sharply Monday. Juno is developing cellular immunotherapies to treat...
BLCM: 28.55 (+2.59), KITE: 57.56 (-1.43), JUNO: 55.72 (-0.68), NVS: 103.45 (-0.62)
Kite Pharma Commends Honors Conferred to Drs. Owen Witte and Steven A. Rosenberg at the 2015 American Association for Cancer Research (AACR) Annual Meeting
GlobeNewswire - Tue Apr 21, 12:30PM CDT
Kite Pharma, Inc. (Kite) (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT(TM)) products for the treatment of cancer, today announced that Owen Witte, M.D., director of the Eli & Edythe Broad Center of Regenerative Medicine & Stem Cell Research at UCLA, is being honored at this year's AACR conference as he receives the prestigious G.H.A. Clowes Memorial Award. In addition, Steven A. Rosenberg, M.D., Ph.D., Chief of Surgery at the National Cancer Institute (NCI), has been inducted into the 2015 Class of Fellows of the AACR Academy. Dr. Witte is a scientific founder of Kite Pharma, serving on Kite's Scientific Advisory Board, and Dr. Rosenberg is a special advisor to Kite.
KITE: 57.56 (-1.43)
Earnings Insights - Kite Pharma
PR Newswire - Tue Apr 21, 8:30AM CDT
Editor Note: For more information about this release, please scroll to bottom.
KITE: 57.56 (-1.43), AMGN: 169.10 (+0.64)
Why Shares of Juno Therapeutics Inc. and Kite Pharma Inc. Crashed Today
Alex Planes, The Motley Fool - Motley Fool - Mon Apr 20, 5:59PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of biotech upstarts Juno Therapeutics and ...
ZIOP: 10.88 (+0.03), KITE: 57.56 (-1.43), JUNO: 55.72 (-0.68), NVS: 103.45 (-0.62)
AACR - Solid Tumour CAR-T Foray Lives Up To Its Low-Key Billing
EP Vantage - at Seeking Alpha - Mon Apr 20, 3:58PM CDT
For some time now solid tumours has been seen as the next big battleground for CAR-T therapy, but based on the underwhelming early data released yesterday at the AACR meeting the best that can be said is that the jury is still out. A very early...
KITE: 57.56 (-1.43), MRK: 57.69 (+0.03), JUNO: 55.72 (-0.68), NVS: 103.45 (-0.62)
Juno, Kite CAR-T Stocks Fall on Disappointing Solid Tumor Data
at The Street - Mon Apr 20, 9:22AM CDT
Shares of Juno Therapeutics and Kite Pharma are weak Monday following a lackluster showing for so-called CAR-T cellular therapies in solid tumors at a closely watched cancer conference this weekend.
ZIOP: 10.88 (+0.03), BLCM: 28.55 (+2.59), KITE: 57.56 (-1.43), JUNO: 55.72 (-0.68)
NeoStem Announces Expanded Cell Therapy Manufacturing Relationship With Kite Pharma
GlobeNewswire - Mon Apr 20, 6:30AM CDT
NeoStem, Inc. (Nasdaq:NBS), a biopharmaceutical company developing novel cell-based individualized medicine therapies, announced today the expansion of manufacturing services under an existing Services Agreement between its wholly-owned subsidiary, PCT, and Kite Pharma, Inc. (Nasdaq:KITE) (Kite), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT(TM)) products for the treatment of cancer.
KITE: 57.56 (-1.43), NBS: 2.88 (+0.06)
Immune Cell Cancer Immunotherapy Passes First Safety Test in Solid Tumors
at The Street - Sun Apr 19, 11:45AM CDT
The positive phase I safety study was conducted using a CAR-T therapy from Novartis and the University of Pennsylvania.
KITE: 57.56 (-1.43), JUNO: 55.72 (-0.68), NVS: 103.45 (-0.62)
The Top 5 Best IPO Performers in the Last Year
at The Street - Thu Apr 16, 2:56PM CDT
These are the top five best IPO performers in the last 12 months.
RDUS: 41.90 (-0.48), KITE: 57.56 (-1.43), CYBR: 65.53 (-0.84), ONCE: 64.79 (-0.25), ATRA: 63.79 (+7.64)
Etsy, Virtu Price High As IPOs Finally Wake Up
at Investor's Business Daily - Wed Apr 15, 6:45PM CDT
The 2015 IPO market is finally starting to pick up the pace after a relatively sleepy start. Etsy (ETSY), an e-commerce site for handmade goods and vintage items, was one of three notable initial public offerings that priced high in their expected...
XBIT: 27.55 (+0.18), VIRT: 21.81 (-0.54), ADRO: 38.17 (-0.50), KITE: 57.56 (-1.43), PRTY: 20.65 (-0.22), CDTX: 14.94 (-0.11), JUNO: 55.72 (-0.68), ETSY: 25.12 (-0.63)
Critical Alerts For GW Pharmaceuticals, Avon Products, 58.com, Box and Kite Pharma Released By InvestorsObserver
PR Newswire - Wed Apr 15, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for GWPH, AVP, WUBA, BOX and KITE.
WUBA: 75.56 (+3.20), AVP: 8.81 (-0.07), BOX: 18.29 (+0.37), KITE: 57.56 (-1.43), GWPH: 113.04 (-0.05)
Why Kite Pharma (KITE) Could Shock the Market Soon - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Apr 15, 8:00AM CDT
Kite Pharma has seen a small negative price movement but large positive earnings estimate revisions make it an unappreciated stock that might have potential for gains
KITE: 57.56 (-1.43)
Celldex Therapeutics Pushes Forward With Varlilumab And Further Proves Its Worth
Investing Healthcare - at Seeking Alpha - Tue Apr 14, 10:05AM CDT
KITE: 57.56 (-1.43), CLDX: 28.95 (+1.08), BMY: 66.60 (-0.21), ONTY: 1.80 (+0.03)
Heat Biologics Is An Opportunity Among Soaring Immunotherapy Biotech Valuations
Sharon di Stefano - Seeking Alpha - Tue Apr 14, 8:20AM CDT
Vaccination, in medical terminology, is injection of a disease-causing microorganism that stimulates the immune system to fight against infection, using the body's own defense mechanisms. Vaccination has all but wiped out polio, tetanus, chicken pox...
HTBX: 7.71 (-0.64), BLCM: 28.55 (+2.59), KITE: 57.56 (-1.43), PFE: 34.93 (+0.04), MRK: 57.69 (+0.03), CLLS: 31.30 (-0.91), SPPI: 5.98 (+0.04), JUNO: 55.72 (-0.68), BMY: 66.60 (-0.21)
Amgen Upgraded to Strong Buy, Perfect for Your Portfolio - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 13, 2:27PM CDT
On Apr 11, Zacks Investment Research upgraded Amgen Inc. (AMGN) to a Zacks Rank #1 (Strong Buy); is it in your portfolio?
CYTK: 7.29 (-0.09), CBM: 42.07 (-0.65), KITE: 57.56 (-1.43), AMGN: 169.10 (+0.64)
Immunotherapy: Unleashing The Immune System To Decimate Cancer
ARK Investment Management - at Seeking Alpha - Sat Apr 11, 2:51AM CDT
By James Bannon, Analyst: Genomics For more than a century, surgery and poison have been the antidotes to cancer. When tumors are discovered, doctors decide whether or not to remove them surgically. With or without surgery, doctors typically...
KITE: 57.56 (-1.43), MRK: 57.69 (+0.03), AMGN: 169.10 (+0.64), JUNO: 55.72 (-0.68), BMY: 66.60 (-0.21), NVS: 103.45 (-0.62)
Kite Pharma to Present at the 2015 Jefferies Immuno-Oncology Summit in Boston
GlobeNewswire - Fri Apr 10, 7:00AM CDT
Kite Pharma, Inc., (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT(TM)) products for the treatment of cancer, today announced that Arie Belldegrun, M.D., FACS, Chairman, President and Chief Executive Officer, will present a company overview at the 2015 Jefferies Immuno-Oncology Summit in Boston. The presentation will take place on Wednesday, April 15, 2015, at 8:10 a.m. EDT.
KITE: 57.56 (-1.43)
Why Investors Shouldn't Worry About Explosive New Drug Pricing: Maxim's Jason Kolbert
Life Sciences Report - Seeking Alpha - Thu Apr 09, 4:59PM CDT
It's the daring Phase 2-stage molecules of today that will bring patients a generation of biotech drugs that could cure certain deadly diseases tomorrow. The candidates that succeed will also energize the portfolios of investors who have exercised...
PSTI: 2.80 (-0.03), NBS: 2.88 (+0.06), OSIR: 16.35 (-0.10), BCLI: 4.29 (-0.09), MDVN: 128.88 (+0.29), INO: 10.39 (-0.09), CYTX: 0.96 (-0.09), STEM: 0.82 (-0.06), JUNO: 55.72 (-0.68), ATHX: 1.34 (+0.01), CUR: 1.96 (-0.04), BLUE: 136.49 (+1.22), VRTX: 132.85 (+0.65), AMGN: 169.10 (+0.64), KERX: 11.52 (-0.15), OMER: 24.41 (-0.15), KITE: 57.56 (-1.43), GILD: 104.18 (-1.02), MRK: 57.69 (+0.03), TEVA: 63.01 (-1.15)
Another IPO Filed In Hot Cancer Immunotherapy Field
at Investor's Business Daily - Tue Apr 07, 12:55PM CDT
Adaptimmune Therapeutics has filed for an initial public offering, adding another company to one of the hottest sectors in the biotech field. U.K.-based Adaptimmune Therapeutics plans to raise up to $150 million and list on the Nasdaq under the...
BLUE: 136.49 (+1.22), BLCM: 28.55 (+2.59), KITE: 57.56 (-1.43), AMGN: 169.10 (+0.64), JUNO: 55.72 (-0.68)
Kite Pharma Announces Publication in Science of Cancer Immunotherapy Articles Authored by Lead Collaborators at the National Cancer Institute and the Netherlands Cancer Institute
GlobeNewswire - Mon Apr 06, 7:00AM CDT
Kite Pharma, Inc. (Kite) (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT(TM)) products for the treatment of cancer, today announced articles being published in the current issue of Science, one article by the Company's Cooperative Research and Development Agreement (CRADA) collaborators at the National Cancer Institute (NCI) and the second article by the Netherlands Cancer Institute (NKI). The first article, "Adoptive Cell Transfer as personalized immunotherapy for human cancer," was authored by Steven A. Rosenberg, M.D., Ph.D., Chief of Surgery at the NCI, and his colleague Nicholas P. Restifo, M.D., Senior Investigator at NCI's Surgery Branch. The second article, "Neoantigens in cancer immunotherapy," was written by Professor Dr. Ton N. M. Schumacher, Ph.D., Deputy Director of NKI, and Robert D. Schreiber, Ph.D., Director, Center for Human Immunology and Immunotherapy Programs, at Washington University School of Medicine. Professor Schumacher also serves as Chief Scientific Officer of Kite Pharma EU.
KITE: 57.56 (-1.43)
